ADD THESE DATES TO YOUR E-DIARY OR GOOGLE CALENDAR
This site is part of the Siconnects Division of Sciinov Group
This site is operated by a business or businesses owned by Sciinov Group and all copyright resides with them.
ADD THESE DATES TO YOUR E-DIARY OR GOOGLE CALENDAR
06 Feb, 2025
In recent years, researchers have started studying de-escalation of cancer treatments. They want to know if the intensity, dose, or number of medicines a person receives could be reduced without affecting how effective the treatment is. They also want to know if treatment de-escalation could cause fewer side effects.
The findings of this study suggest that Abraxane before surgery kills more cancer cells and causes fewer side effects than the standard chemotherapy regimen of Taxotere and carboplatin for early-stage HER2-positive disease.
If more studies confirm these findings, the researchers say Abraxane plus Herceptin and Perjeta before surgery might become a new standard of care for early-stage HER2-positive disease.